S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NYSE:ABBV

AbbVie Stock Forecast, Price & News

$110.86
-0.40 (-0.36 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$109.48
Now: $110.86
$111.60
50-Day Range
$102.80
MA: $106.83
$112.62
52-Week Range
$62.55
Now: $110.86
$113.41
Volume5.19 million shs
Average Volume7.54 million shs
Market Capitalization$195.72 billion
P/E Ratio23.44
Dividend Yield4.67%
Beta0.84
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
AbbVie logo

MarketRank

Overall MarketRank

2.81 out of 5 stars

Medical Sector

2nd out of 1,925 stocks

Pharmaceutical Preparations Industry

1st out of 773 stocks

Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 5.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900
Employees30,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.36 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Outstanding Shares1,765,474,000
Market Cap$195.72 billion
Next Earnings Date2/3/2021 (Confirmed)
OptionableOptionable
$110.86
-0.40 (-0.36 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock price been impacted by Coronavirus (COVID-19)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABBV shares have increased by 30.7% and is now trading at $110.86.
View which stocks have been most impacted by COVID-19
.

Is AbbVie a buy right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AbbVie?

Wall Street analysts have given AbbVie a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AbbVie wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Larry J. Merlo's approval rating as AbbVie's CEO?

6,978 employees have rated AbbVie CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among AbbVie's employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for AbbVie
.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Wednesday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) issued its quarterly earnings results on Friday, October, 30th. The company reported $2.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.75 by $0.08. The company earned $12.88 billion during the quarter, compared to analysts' expectations of $12.71 billion. AbbVie had a return on equity of 439.24% and a net margin of 18.16%. AbbVie's revenue for the quarter was up 51.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.33 earnings per share.
View AbbVie's earnings history
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, October 30th. Shareholders of record on Friday, January 15th will be given a dividend of $1.30 per share on Tuesday, February 16th. This represents a $5.20 dividend on an annualized basis and a yield of 4.69%. The ex-dividend date of this dividend is Thursday, January 14th. This is a boost from AbbVie's previous quarterly dividend of $1.18.
View AbbVie's dividend history
.

Is AbbVie a good dividend stock?

AbbVie pays an annual dividend of $5.20 per share and currently has a dividend yield of 4.67%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. AbbVie has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 58.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AbbVie will have a dividend payout ratio of 42.73% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2020 Pre-Market earnings guidance on Friday, October, 30th. The company provided earnings per share (EPS) guidance of 10.47-10.49 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.42.

What price target have analysts set for ABBV?

21 brokerages have issued 1-year price objectives for AbbVie's shares. Their forecasts range from $95.00 to $128.00. On average, they expect AbbVie's stock price to reach $112.50 in the next twelve months. This suggests a possible upside of 1.5% from the stock's current price.
View analysts' price targets for AbbVie
or view Wall Street analyst' top-rated stocks.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 66, Pay $7.11M)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 54, Pay $3.98M)
  • Mr. Robert A. Michael, Exec. VP & CFO (Age 50, Pay $2.76M)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 57, Pay $4.3M)
  • Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 57, Pay $4.08M)
  • Dr. Azita Saleki-Gerhardt, Exec. VP of Operations (Age 57)
  • Dr. Thomas J. Hudson, Sr. VP of R&D and Chief Scientific Officer (Age 58)
  • Ms. Elizabeth Shea, VP of Investor Relations
  • Mr. Timothy J. Richmond, Exec. VP & Chief HR Officer (Age 54)
  • Mr. Scott C. Brun M.D., VP of Scientific Affairs & Head of AbbVie Ventures

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional investors include Gateway Investment Advisers LLC (0.04%), Candriam Luxembourg S.C.A. (0.03%), RNC Capital Management LLC (0.03%), Donaldson Capital Management LLC (0.03%), Rhenman & Partners Asset Management AB (0.03%) and TIAA FSB (0.03%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie
.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., DNB Asset Management AS, Avantax Advisory Services Inc., Contravisory Investment Management Inc., Transform Wealth LLC, Gateway Investment Advisers LLC, Pacer Advisors Inc., and Exchange Traded Concepts LLC. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, Richard A Gonzalez, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
or view top insider-selling stocks.

Which major investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Kestra Advisory Services LLC, Fulton Breakefield Broenniman LLC, Founders Capital Management, Oak Harvest Investment Services, American National Bank, Tandem Investment Advisors Inc., and Liberty Capital Management Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie
or or view top insider-buying stocks.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $110.86.

How big of a company is AbbVie?

AbbVie has a market capitalization of $195.72 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.